Story
Abcellera Biologics Shares Decline on $200 Million Stock Offering News

Shares of Abcellera Biologics (ABCL) fell 4.1% in after-hours trading after the company announced its intent to launch a proposed underwritten public offering. The move to raise capital comes just one day after the stock surged on promising clinical trial results.
The Offering Details
Abcellera plans to offer $200 million in common shares and pre-funded warrants, with the company receiving all proceeds from the sale. According to the announcement, the capital is intended to fund research, development, and clinical advancement for its internal pipeline, particularly its lead program, ABCL635.
The funds will also be used for working capital and general corporate purposes. The offering is being managed by a syndicate of banks, with Jefferies, J.P. Morgan, Cantor, UBS Investment Bank, and BMO Capital Markets acting as joint book-running managers.
Market Reaction and Context
The after-hours stock decline is a direct reaction to the dilutive nature of the offering. By issuing new shares, a company increases the total number of shares outstanding, which can reduce the ownership percentage and earnings per share for existing investors.
AdThe timing of the capital raise is notable, as it follows a roughly 35% surge in Abcellera's stock price during the prior trading session. The company is capitalizing on a recent 52-week high of $10.29 to raise funds at a more favorable valuation.
Positive Clinical Catalyst
The preceding rally was fueled by positive data from a Phase 2 trial of ABCL635, a potential first-in-class antibody for treating hot flashes in menopausal women. The company reported the drug delivered an 83% mean reduction in hot flash frequency at week four.
Following the news, Truist Securities raised its price target on the stock to $30 from a previous $12, maintaining a Buy rating. The firm cited increased peak risk-adjusted sales estimates for ABCL635, projecting potential sales of $1.1 billion.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.